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Objective: Lumican (LUM) is a major extracellular matrix glycoprotein in adult articular cartilage and its
expression is known to be upregulated upon cartilage degeneration. LUM is associated with the
pathogen-associated molecular pattern (PAMP) activation of the TLR4 signalling cascade, with TLR4
being highly associated with inﬂammation in rheumatic diseases. However, the main role of the LUM
structural molecule in osteoarthritis (OA) remains elusive. The aim of this study was, therefore, to un-
derstand the role of LUM during TLR4-mediated activation in OA.
Methods: After measuring LUM levels in synovial ﬂuid (SF) of OA patients and lipopolysaccharide (LPS)-
induced TLR4 activation, the role of LUM in the expression of pro-inﬂammatory molecules and cartilage
degradation was assessed in vitro and ex vivo in a cartilage explant model. Primary macrophage acti-
vation and polarization were studied upon LUM co-stimulation with LPS.
Results: We demonstrate that LUM is not only signiﬁcantly upregulated in SF from OA patients compared
to healthy controls, but also that LUM increases lipopolysaccharide (LPS)-induced TLR4 activation.
Furthermore, we show that a pathophysiological level of LUM augments the LPS-induced TLR4 activation
and expression of downstream pro-inﬂammatory molecules, resulting in extensive cartilage degradation.
LUM co-stimulation with LPS also provided a pro-inﬂammatory stimulus, upregulating primary
macrophage activation and polarization towards the M1-like phenotype.
Conclusions: These ﬁndings strongly support the role of LUM as a mediator of PAMP-induced TLR4
activation of inﬂammation, cartilage degradation, and macrophage polarization in the OA joint and
potentially other rheumatic diseases.
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Osteoarthritis (OA), is a leading cause of disability worldwide1
with incidence levels reaching 36% of the US adult population2.
Treatment options are not only limited by a lack of understanding
of the molecular events involved in OA disease stages but also
because OA has multiple disease phenotypes. While trauma is often
an early traceable event leading to symptomatic OA, current the-
ories on OA pathogenesis also propose an intrinsic interaction be-
tween joint damage and chronic inﬂammation3. The innate
immune system and associated inﬂammation have been shown totd. All rights reserved.
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events during OA are associated with the activity of the innate
immune system, including inﬁltration and inﬂammatory activation
of macrophages6 and activation of the Toll-like receptor (TLR)
pathway7 and complement system8.
As part of the inﬂammatory pathways driving OA progression,
initial inﬂammatory responses to cartilage damage are mediated by
receptors, including TLRs. TLRs are a group of membrane-
associated pattern-recognition receptors (PRRs) that recognize
endogenous and exogenous danger-associated molecular patterns
(DAMPs) such as cartilage matrix fragments from ﬁbronectin9,
hyaluronan10, biglycan11, among others, while also responding to
pathogen-associated molecular patterns (PAMPs) such as lipo-
polysaccharide (LPS)12. In OA, activation of TLRs via the NF-kB
pathway leads to the secretion of cytokines and chemokines such as
TNF, interleukin 6 (IL-6) and matrix metalloproteinases (MMPs), as
well as the downregulation of collagen and proteoglycan synthe-
sis13. When tissue is damaged and degraded during OA, extracel-
lular matrix (ECM) proteins may be released, fragmented and
turned into signaling molecules capable of interacting with TLRs to
trigger an innate immune response14,15.
Small leucine-rich proteoglycans (SLRPs) are a group of impor-
tant biologically active ECM components found in all tissues16. Once
thought to be purely structural matrix-bound components, SLRPs
have now been associated with pathogenic mechanisms of several
diseases and disorders such as osteoporosis, muscular dystrophy,
among others17. Intriguingly, SLRPs are also known to activate and
regulate the activity of the immune system18,19. The expression of
SLRPs is altered with disease state during OA progression, which
consequently affects key structural, organizational and biological
properties such as cartilage collagen network assembly as well as
growth factor signalling, e.g., TGF-b20. Moreover, SLRPs such as
biglycan and ﬁbromodulin are increasingly fragmented and
released into the synovial ﬂuid (SF), ultimately resulting in their
depletion from OA cartilage21,22. Once released, SLRPs can exert
biological effects such as immune responses on synovial tissue
resident cells, including synoviocytes, ﬁbroblasts, and macro-
phages, among others7.
Lumican (LUM) is a member of the SLRP family best known for
its interactionwith ﬁbrillar collagens23 and has recently emerged as
a participant in hostepathogen interactions. LUM is known to
interact with TLR4-ligand LPS, and LUM KO mice are hypo-
responsive to LPS-induced septic shock24,25. Strikingly, LUM
expression is signiﬁcantly fragmented and reduced in OA cartilage
(with fragmentation accounting for less than 50% of total protein)
but is also upregulated in serum and SF of OA patients21,22. The
increased presence of LUM in SF thus raises the question if dysre-
gulated levels of LUM impact immune responses in the OA joint,
particularly together with OA pathophysiological molecules such as
LPS26.
Macrophages are key players of the innate immune system and
are associated with inﬂammation and pathogenesis of many dis-
eases, including OA27. In response to various stimulators, macro-
phages may undergo classical M1 activation or alternative M2
activation28. Although it is known that macrophages are activated
during OA29, the role of overexpressed LUM in this process is not
understood.
The goal of this study was to characterize how overexpression of
LUM contributes to LPS-induced low-grade inﬂammation,
chondrocyte-mediated cartilage destruction and regulation of
macrophage polarization and immune system activation in OA. Our
data demonstrate that overexpressed LUM contributes to the
innate immune-mediated pathogenesis of primary OA, with po-
tential implications in other rheumatic diseases.Materials and methods
Synovial ﬂuid collection
SF samples from knee meniscectomy, end-stage knee OA, knee
rheumatoid arthritis (RA), and carpometacarpal thumb joint (CMC-
I) OA patients were collected prior to surgical incision. SF collection,
and patient inclusion and exclusion criteria details are described in
the supplementary material.Enzyme-linked immunosorbent assay
Non-fragmented LUM was measured in SF (1:50) and chon-
drocyte culture media (1:1) by sandwich enzyme-linked immu-
nosorbent assay (ELISA) (cat. DY2846-05, R&D Systems, US),
according to manufacturer instructions.SEAP NF-kB activity assays
The TLR4/NF-kB activity was measured using the HEK-hTLR4
and THP-1 dual™ cells-based reporter gene assays according to
the manufacturer's instructions (cat. hkb-htlr4, thpd-nﬁs, Inviv-
oGen, CA, USA). Upon recognition of an agonist, TLR4 activation
results in NF-kB activation and SEAP reporter gene activation. This
leads to the secretion of alkaline phosphatase, which was quanti-
ﬁed by a colorimetric assay (cat. QUANTI-Blue; InvivoGen).
HEK-hTLR4 cells were cultured according to the manufacturer's
instructions (InvivoGen) and as previously described. Cells were
stimulated with a dose series of recombinant LUM (cat. 2846-LU,
R&D Systems) and with 10 ng/ml LPS from Escherichia coli (strain
K12) as a positive control. In a separate experiment, cells were
stimulated with 1 mg/ml LUM in combination with a dose series of
LPS from E. coli (strain K12) (cat. tlrl-peklps, Invivogen) or Bacter-
oides dorei (isolated as previously described30) for 24 h. To study if
increased amounts of LUM augment the OA SF induction of TLR4
activation, HEK-hTLR4 cells were stimulated with OA SF, or OA SF
spiked with LUM. LPS stimulation was used as a positive control.
THP1-Dual™ cells were cultured and differentiated into Mф
(naïve macrophages) as previously described31. Mф were stimu-
lated with 10 ng/ml LPS, or 1 mg/ml LUM or a combination of the
two for 24 h. In selected conditions, 1 mM of TLR4 inhibitor CLI095
(cat. tlrl-cli95, InvivoGen) was added for 30 min prior to the addi-
tion of LPS or LUM.Flow cytometry
LUM was labelled with FITC using a commercially available
labelling kit according to the manufacturer's recommendation (cat.
46950, Sigma). Association of LUM with TLR4 was studied after
incubation of HEK-293 and HEK-Blue™ hTLR4 cells (InvivoGen)
with FITC-LUM (1 mg/ml). Cell-associated ﬂuorescence was
analyzed using BD FACSAria™ III (BD Biosciences) with identical
acquisition parameters in all experiments. Human articular chon-
drocytes were analyzed for the expression of LC3B cytosolic marker
of autophagy (cat. 8899S, Cell Signalling) by ﬂow cytometry using
the BD FACSVerse™ (BD Bioscience). Brieﬂy, cells were washed
with PBS, centrifuged (300 rcf, 5 min), and the supernatant dis-
carded. Cells were incubated with the chondrocyte positive marker
antibodies CD44 (cat. 17-0441-81, eBioscience), CD90 (cat. 561558,
BD Bioscience) (15min, RT), followed by 15min of permeabilization
(cat. 554714, BD Biosciences) and staining with LC3B (15min, RT),
followed by washing with PBS, and resuspension in PBS-EDTA-BSA.
All data was processed in Flowjo software (Flowjo LLC).
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explant culture maintenance
Patient recruitment, participation, and sample collection were
approved by the local cantonal ethics committee, Zürich,
Switzerland (BASEC Nr. PB_2017-00510) with patient signed
informed consent. Samples were collected from patients who un-
derwent arthroscopic reconstruction (N ¼ 4), and OA patients who
underwent total knee arthroplasty (TKA) (N ¼ 4).
Human chondrocytes and OA cartilage explants were isolated
from the lateral tibial plateau region. Cartilage extraction and
chondrocytes culture details are provide in the supplementary
material.
Stimulation of primary chondrocytes and cartilage explant cultures
Chondrocytes were stimulated with 10 ng/ml LPS, 1 mg/ml LUM,
or a combination of both for 24 h. In selected conditions, 1 mM of
TLR4 inhibitor CLI095 was added for 30 min prior to the addition of
LPS or LUM. Cartilage explants were maintained for 3e4 days and
stimulated in identical conditions to chondrocytes during 48 h.
Lactate dehydrogenase activity assay
Cytotoxicity was assessed 24 h post-stimulation of chon-
drocytes. Brieﬂy, lactate dehydrogenase (LDH) activity in the
conditioned medium of monolayer chondrocyte cultures was
determined after 24 h, according to the manufacturer's instructions
(cat. 4744926001, Roche, Penzberg, Germany).
Macrophage differentiation and polarization studies
To study the effect of LUM on macrophage polarization, human
blood-derived monocytes were used. Peripheral blood was ob-
tained from donors under informed consent according to approval
from the local cantonal ethics committee, St. Gallen, Switzerland
(BASEC Nr. PB_2016-00816) and peripheral blood mononuclear
cells (PBMC) were isolated via ﬁcoll gradient separation and sub-
sequent negative selection using monocyte isolation kit II (cat. 130-
091-153, Miltenyi Biotec). Puriﬁed monocytes were suspended in
RPMI-1640 medium supplemented with 10% FBS, 1% penicillin-
streptomycineneomycin mixture (cat. 15640, ThermoFisher) and
2 mM l-glutamine. Seeded at a cell density of 1  105 cells/cm2,
monocytes were differentiated with 20 ng/ml human macrophage
colony stimulating factor (M-CSF, cat. PHC9501, Invitrogen,
Switzerland) for 6 days. The medium was refreshed on day 3. To
induce polarization, 50 ng/ml LPS (cat. L7770, Sigma) were used for
M1-like polarization, whereas 20 ng/ml IL-4 (cat. 130-093-921,
Miltenyi Biotec) were used for M2-like polarization for 24 h. To test
the effect of LUM, 10 ng/ml of LUM were added with or without
polarization substance. Thereafter, total RNA (RNAeasy micro kit,
Qiagen) and supernatants were collected. cDNA was produced
(ThermoScript real-time-PCR System, Invitrogen) and quantitative
real-time PCR was performed (iCycler iQ Real-Time PCR Detection
System, Bio-Rad) using SYBR Green I (Applied Biosystems). Primer
sequences are provided in Supplementary Table 1.
Protein measurements using luminex xMAP® technology
Protein levels were measured using the xMAP® technology
(Luminex, Austin, TX, USA). Chondrocyte and macrophage culture
supernatants were harvested and MMP-1, MMP-13, IL-6, IL-10, and
TNF-a were measured using ProcartaPlex immunoassays (Ther-
moﬁsher) and read by a MAGPIX® system (ThermoFisher) accord-
ing to the manufacturer's instructions.Histology and immunoﬂuorescence
Cartilage explant samples were formaldehyde ﬁxed and
sectioned to a thickness of 5 mm, as previously described31. Tissue
sections were then pre-treated with 0.1% hyaluronidase and
blocked with 5% BSA. For staining of LUM, sections were incubated
with lumican antibody (cat. AF2846, 1:20, R&D Systems) followed
by secondary antibody rabbit anti-goat IgG Alexa Fluor 488 (cat.
A27012,1:2000, Invitrogen) and DAPI nuclear staining. For Col2 and
Col10 stainings, the sections were incubated with anti-Col2 (cat.
600-401-104S, 1:200, Rockland) and anti-Col10 (cat. ab49945,
1:300, Abcam) antibodies followed by secondary antibodies Alex-
aFluor 488 goat anti-rabbit IgG (cat. A11008,1:200, Invitrogen,) and
AlexaFluor 594 goat anti-mouse IgG (cat. A110058, 1:200, Invi-
trogen) and DAPI nuclear staining. Safranin-O stainings were per-
formed as previously described31.
Primary chondrocytes were ﬁxed with 4% PFA and per-
meabilized by 0.1% Triton-X. 1% BSA was used for blocking non-
speciﬁc binding. To stain for apoptotic marker cleaved caspase-3
(CC3), chondrocytes were incubated with antibody CC3 (cat.
MAB835, 1:200, R&D Systems) followed by incubation with sec-
ondary antibody AlexaFluor 488 goat anti-rabbit IgG (cat. A11008,
Life Technologies) and DAPI nuclear staining.
All immunoﬂuorescence stainings were imaged using a Zeiss
Axio Observer (Carl Zeiss Microscopy GmbH, Thuringia, Germany).
Only Safranin-O stained samples were imaged using a Slide Scanner
(Pannoramic 250, 3D Histech).
Statistical analysis
Statistical analysis was performed using Graph Pad Prism 4.0 or
higher versions. KruskalleWallis test was used to analyzed the LUM
ELISA (LUM levels in SF, and LUM secretion by chondrocytes), LDH
activity and macrophage polarization protein markers, followed by
Dunn's post hoc test. One-way ANOVA was used to analyze chon-
drocyte catabolic markers, and HEK-hTLR4 stimulation with OA SF,
followed by Tukey's post hoc test. Two-way ANOVA was used to
analyze RT-PCR, remaining HEK-TLR4 related experiments, and
THP1 NF-kB activation, followed by Tukey's post hoc test. *p < 0.05,
**p < 0.01, ***p < 0.001, ****p < 0.0001.
The choice of N ¼ 4 biological replicates with n ¼ 3 technical
replicates in general for the experiments was considered to have
sufﬁcient power (calculated by post-hoc power analysis) for
exploratory analyses.
Results
The concentration of secreted LUM in the SF of OA patients,
either with knee or CMC-I OAwere compared to “healthy” controls
(meniscectomy patients), as well as to RA as a positive control with
inﬂammatory arthritic condition [Fig. 1(a)]. Interestingly, LUM
levels of knee OA and RA SF were signiﬁcantly upregulated vs
meniscectomy control, but also higher vs CMC-I OA. As cartilage is a
major source of LUM in joints, we analyzed LUM expression in
osteoarthritic cartilage tissue and chondrocytes upon LPS stimu-
lation [Fig. 1(b)]. Strikingly, LPS-induced inﬂammation led to a
drastic reduction of LUM in articular cartilage, particularly in the
cartilage surface zone. Moreover, chondrocyte secretion of LUM
was signiﬁcantly increased by LPS and pro-inﬂammatory cytokine
IL-1b stimulation, although not signiﬁcantly in IL-1b condition
[Fig. 1(c)]. Together, these data suggest that LUM secretion is
signiﬁcantly increased in an OA inﬂammatory environment.
Since the LUM structure contains a leucine-rich repeat (LRR)
domain that may be recognized by TLR4, LUM alone may act as a
TLR4-DAMP, triggering and/or binding to TLR432,33. We, therefore,
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reporter cell line, it could be observed that LUM alone does not
trigger TLR4 activation independent of the dose [Fig. 2(a)].
Furthermore, FACS analysis conﬁrmed that LUM-FITC does not bind
with a higher degree to the HEK-TLR4 cell line in comparison to the
TLR4-absent parental cell line HEK-293T [Fig. 2(b)], neither was the
binding degree affected by TLR4 antibody [Fig. 2(c)].
To conﬁrm that LPS-induced TLR4 activation is mediated by
LUM, we studied LPS-induced TLR4-activation in the presence of
LUM. Interestingly, increasing levels of LUM (as observed in OA
synovial ﬂuid) augmented LPS-induced TLR4 activation in the HEK-
hTLR4 reporter cell line, independent of the gram-negative bacte-
rial origin of LPS [Fig. 3(a)]. Given the presence of LPS, but also other
known DAMPs in OA SF, we also studied if spiking OA SF with LUM
would increase TLR4 activation. Notably, OA SF-induced TLR4
activation was signiﬁcantly upregulated upon spiking with LUM
[Fig. 3(b)].
In order to understand how chondrocytes respond to LPS co-
stimulation with LUM, typical features observed in OA cartilage
such as the release of pro-inﬂammatory molecules, cell death,
apoptosis, and cartilage degradation and remodeling were
assessed. LUM co-stimulation with LPS signiﬁcantly upregulated
chondrocyte secretion of key OA molecules IL-6 and metal-
loproteinases 1 and 13 (MMP-1, MMP-13) in a TLR4-dependent
manner [Fig. 4(a)]. TLR4 inhibitor CLI095 co-stimulation demon-
strated that LUM does not trigger TLR4 activation or that LUM re-
combinant protein is not contaminated with endotoxins.
Interestingly, not only inﬂammation but also cytotoxicity was
signiﬁcantly increased upon LUM co-stimulation with LPS
[Fig. 4(b)]. When staining chondrocytes with the apoptotic marker
CC3, a marked upregulation could be observed upon LUM co-
stimulation with LPS [Fig. 4(c)]. Autophagy was also a cell death
mechanism taking place as evident by the upregulation of auto-
phagy marker LC3B by LUM co-stimulation with LPS upon Flow
Cytometry measurements (Supplementary Fig. 1).
Cartilage degradation was analyzed using an OA cartilage
explant culture model. When explants were stimulated with the
same concentrations of LPS and LUM as in 2D culture, cartilage
degradation, as a result of OA disease, could be observed in all
donors [Fig. 5(a)]. LPS stimulation resulted in increased proteo-
glycan depletion, but also surface ﬁbrillation. More importantly,
LUM co-stimulation with LPS had a striking effect on proteoglycan
depletion and surface ﬁbrillation in all donors. Collagen type II
degradation and collagen type X were also studied [Fig. 5(b)],
showing markedly downregulated collagen type II upon LUM co-
stimulation with LPS and LPS alone when compared to control. InFig. 1. Presence of LUM in OA synovial ﬂuid, cartilage and LUM secretion by chondrocytes. (a
(N ¼ 40), CMC-I OA SF (N ¼ 11), and RA SF (N ¼ 20) (b) LUM content in OA cartilage wi
inﬂammatory stimulation by LPS and IL-1b. Values are mean ± SD (n > 3).parallel, the hypertrophy marker collagen type X was upregulated
by LUM co-stimulation with LPS, when compared to LPS alone and
control.
To determine whether LUM has an effect on macrophage po-
larization, human macrophages were treated with a pro-
inﬂammatory stimulus (i.e., LPS) or an anti-inﬂammatory stim-
ulus (i.e., IL-4) in presence or absence of LUM and gene expression
proﬁles of pro-inﬂammatory TNF-a and CD197 as well as anti-
inﬂammatory CCL22 and CD206 (Fig. 6) were assessed. RT-PCR
results showed signiﬁcantly increased TNF-a and CD197 levels
upon LUM co-stimulation with LPS [Fig. 6(a) and (b)]. Conversely,
LUM co-stimulation suppressed the expression of CD206 and
CCL22 in IL-4 treated macrophages [Fig. 6(c) and (d)]. While LUM
dramatically affected polarization in LPS or IL-4 treated macro-
phages, LUM alone did not show a signiﬁcant difference in the
expression of polarization markers with the exception of CD197
expression.
The effect of LUM co-stimulation with LPS on the gene expres-
sion of pro-inﬂammatory and anti-inﬂammatory cytokines was
further conﬁrmed by monitoring their protein levels as well as NF-
kB activation in macrophages. Macrophage polarization by LPS lead
to elevated levels of pro-inﬂammatory cytokine TNF-a, and co-
stimulation with LUM resulted in a further increase of TNF-a
levels [Fig. 7 (a)]. Protein expression of the anti-inﬂammatory
marker IL-10 corroborated the RT-PCR results. While IL-4 stimula-
tion showed a signiﬁcant increase in IL-10 expression, co-
stimulation with LUM resulted in lower IL-10 cytokine expression
[Fig. 7(b)]. THP1 derived macrophages showed a dose-dependent
NF-kB activation in response to LPS, which was further enhanced
by co-stimulation with LUM [Fig. 7(c)], and was TLR4-dependent
(CLI095).Discussion
Given the increasing incidence and prevalence of OAworldwide,
a detailed understanding of the molecular mechanism underlying
OA pathogenesis is crucial for the discovery of effective treatments.
Matrix biology is an essential part of OA pathogenesis research,
ranging from cartilage ECM matrix degeneration studies, to the
biological activity of major matrix proteins, and to the development
of OA biomarkers7,34. Here, we demonstrated that cartilage matrix
protein LUM is signiﬁcantly upregulated in knee OA SF relative to
knee meniscectomy patients, and is comparable to RA patient
levels. As LUM is synthesized by chondrocytes and deposited in the
articular cartilage matrix35, cartilage degradation may also release
SLRPs like LUM from the matrix, which leads to their accumulation) LUM levels in synovial ﬂuid from arthritic conditions. Meniscectomy SF (N ¼ 11), OA SF
th and without LPS-stimulation (c) Amount of LUM secretion by chondrocytes under
Fig. 2. LUM-induced TLR4-activation and binding of LUM to TLR4 receptor (a) SEAP reporter gene expression by TLR4/NF-kB activation upon stimulation with increasing doses of
LUM. LPS is the positive control. (b) FACS measurements of LUM-FITC signal upon binding to TLR4 and non-TLR4 HEK 293 cells after 24 h incubation, in order to study the LUM
binding to TLR4. (c) LUM-FITC binding to HEK-TLR4 cells in PBS or in the presence of TLR4 antibody, after 24 h incubation. Values are mean ± SD (n > 6).
Fig. 3. Lumican co-stimulation with LPS and OA synovial ﬂuid and ensuing TLR4/NF-KB activation. (a) SEAP reporter gene activation by TLR4/NF-kB activity upon LUM co-
stimulation by a dose-series of LPS of different bacterial origin. (b) LUM spiking of OA synovial ﬂuid and ensuing TLR4/NF-kB activation, measured by a SEAP reporter gene
assay. Values are mean ± SD (n > 4).
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numerous molecular interactions and inﬂammatory responses7.
Several studies have reported an upregulation of SLRP fragments,
including LUM, in both human OA and OA animal models as po-
tential OA biomarkers21,36. Our results are in line with previous
studies, where LUM was found to be upregulated in OA cartilage at
the mRNA expression level36. Strikingly, RA and OA synovium and
cartilage have been shown to contain LUM antigen complexed to
IgG, which further suggests that LUM may contribute to arthritic
inﬂammation37.
During OA, TLRs expression is upregulated in cartilage and
synovium cells13. In this study, we demonstrate that intact LUM in
SF augments LPS-induced inﬂammatory responses in a TLR4
dependent manner. This is of particular importance since LPS is
associated with OA disease activity and proposed to be a mediator
of OA pathogenesis26,38. Strikingly, LPS stimulation of cartilage
explants led to a drastic reduction of LUM in the cartilage surface
zone. LPS-induced cartilage degradation might explain the
observed depletion of LUM from cartilage and its concomitant
increase in OA SF. Intriguingly, LUM was overexpressed in the
pericellular matrix surrounding chondrocytes. This can poten-
tially be explained by the renewed LUM synthesis uponinﬂammatory stress, as reported previously39,40. Moreover, LPS
and IL-1b stimulation, two important OA pathophysiological
molecules, led to increased secretion of LUM, providing further
evidence of LUM association with inﬂammatory events in OA
pathogenesis.
Although LUM was shown to interact with LPS, LUM alone did
not bind toTLR4, nor did it trigger an inﬂammatory response. This is
supported by ﬂowcytometry analysis, where FITC-labelled LUMdid
not change binding rates to HEK-TLR4 when compared to parental
HEK-293 cell line, or when TLR4-binding was inhibited by TLR4
antibody.
In order to better understand the impact of LUM overexpression
on LPS-induced inﬂammatory responses, we used the HEK-TLR4
reporter cell line for monitoring NF-kB activity, as well as human
primary chondrocytes and macrophages, two essential OA joint
cells. In line with previous reports where LUM KO cells inhibited
LPS-induce NF-kB activation24, we observed that the presence of
LUM also regulates and augments LPS-induced NF-kB activity, in-
dependent of the LPS dose, LPS bacterial origin and hence LPS in-
ﬂammatory nature. This is especially relevant since multiple LPS
types might be present in the OA joint41. The levels of LPS in SF can
be considerable (~5 ng/ml)26, and when spiking OA SF with
Fig. 4. Pro-inﬂammatory marker secretion, cell death, and apoptosis by co-stimulation of LUM and LPS in chondrocytes. (a) IL-6, MMP-1, and MMP-13 induced secretion upon
stimulation by LUM, LPS, or both. CLI095 was used to observe TLR4 dependent effects. (b) Chondrocyte cell death, measured by LDH activity, after LUM co-stimulation with LPS. (c)
Apoptotic marker cleaved caspase three immunostaining after LUM co-stimulation with LPS. Values are mean ± SD (n > 3) from four biological replicates (N ¼ 4).
Fig. 5. Cartilage degradation and remodeling upon LUM co-stimulation with LPS. (a) Cartilage proteoglycan content, indicated by Safranin-O staining, upon LUM co-stimulation
with LPS after 24 h. (b) Collagen type II (green) and X (red) immunostaining reﬂecting their distribution in cartilage explants upon LUM co-stimulation with LPS after 24 h.
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lated NF-kB activation when compared to OA SF alone. This
demonstrated in vitro that LUM overexpression in OA SF causes an
exacerbated inﬂammatory activation, further supporting the
pathophysiological role of LUM in OA. Besides, we also showa novel
function of LUM, not only as being essential for LPS-induced pro-
inﬂammatory responses, as shown previously with the abrogation
of LPS-induced effects in LUM KO cells by Wu et al.24, but also that
overexpression of LUM exacerbates LPS-induced inﬂammatory
responses.Given the potential relevance of LUM in OA disease activity, we
further studied its effects on chondrocytes, given their essential
contribution for cartilage homeostasis, but also for OA progres-
sion42. In line with the results on NF-kB activity, LUM signiﬁcantly
upregulated LPS-induced secretion of catabolic markers IL-6, MMP-
1 and MMP-13, when compared to control and LPS alone. These
responses were TLR4-dependent, as indicated by the lack of
response upon addition of TLR4 inhibitor CLI095. The upregulation
of catabolic markers is an important observation, as MMP-1 and
MMP-13 play a major role in cartilage degradation in OA, while IL-6
Fig. 6. Effect of LUM on macrophage polarization. Human macrophages were cultivated in the presence or absence of LUM and expression proﬁles were assessed for pro-
inﬂammatory TNF-a after 6 h of treatment (a) and CD197 after 24 h of treatment (b) as well as for anti-inﬂammatory CD206 (c) and CCL22 (d) after 24 h. Values are
mean ± SD (n > 5) from three biological replicates (N ¼ 3).
Fig. 7. Secretion of inﬂammatory proteins and NF-kB activity of macrophages upon LUM co-stimulation with LPS. (a) Protein levels of pro-inﬂammatory TNF-a and (b) anti-
inﬂammatory IL-10 after 24 h of treatment. (c) NF-kB activity upon LUM co-stimulation with increasing dose of LPS using a THP1 reporter cell line. CLI095 inhibitor of TLR4
was used to observe TLR4 dependent effects. Values are mean ± SEM (n > 3) from three biological replicates (N ¼ 3).
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and recruit professional immune cells to the synovium43. Paral-
leling the increased pro-inﬂammatory response by LUM co-
stimulation with LPS, cell death was also signiﬁcantly upregulated
in a TLR4 dependent manner when compared to control and LPS.
Chondrocyte death is a feature of OA and is known to be associated
with TLR4 activation, often through apoptosis and autophagy
mechanisms44,45. Strikingly, we observed that both apoptotic
biomarker CC3 and autophagy LC3B marker were increased in
chondrocytes that were LUM co-stimulated with LPS when
compared to the reduced expression of both makers in LPS treated
or control cells, respectively. This is in good agreement with pre-
vious reports46.
To demonstrate the catabolic inﬂuence of LUM on resident
chondrocytes in a matrix-regulated environment, we used anex vivo cartilage explant model47. LUM co-stimulation with LPS or
LPS alone lead to a loss of collagen type II immunostaining in
cartilage explants when compared to control. This can potentially
be explained by the observed upregulation of MMP-1 and MMP-13
by LUM co-stimulation with LPS. Furthermore, collagen type X
expression increased upon LUM co-stimulation with LPS, which is
of particular importance since collagen type X is synthesized by
hypertrophic chondrocytes and represents a hallmark of OA48.
Together, the downregulation of collagen type II and upregulation
of type X are in line with current theories where cartilage degra-
dation by proteases and a dysregulated chondrocyte phenotype
result in a vicious cycle of OA disease49. Notably, LUM co-
stimulation with LPS led to severe degradation of proteoglycans
(which are tightly intercalated with the collagen network) when
compared to controls, as indicated by the reduction of Safranin-O
Fig. 8. Pathogenic role of lumican in the osteoarthritic joint. Upon degeneration of articular cartilage, matrix proteins such as the lumican glycoprotein are released in increased
amounts which left unchecked may have potentially deleterious effects. Soluble lumican (LUM) may interact with pathogenic molecules such as lipopolysaccharide (LPS) upre-
gulating it's proinﬂammatory properties, particularly through NF-kB activation. LUM-LPS has a broad impact in the joint physiology by triggering chondrocytes catabolic response,
characterized by the secretion of matrix proteases and cytokines, leading to further degradation of articular cartilage. Furthermore, LUM-LPS may penetrate the synovium and
impact inﬁltrating and resident MFmacrophages by dysregulating their polarization towards the pro-inﬂammatory M1 macrophage population and ensuing burst cytokine release.
G. Barreto et al. / Osteoarthritis and Cartilage 28 (2020) 92e101 99staining. LPS stimulation has been demonstrated previously to
cause a loss of proteoglycan content in cartilage explants46.
Besides chondrocytes, macrophages are key cells involved in the
regulation of joint inﬂammation and erosion. It has been shown
previously that macrophages transition from a pro-inﬂammatory
(M1) to an anti-inﬂammatory (M2) state in OA29,50. However, the
role of LUM in this process is currently unknown. To the best of our
knowledge, this is the ﬁrst study showing that LUM has a regula-
tory effect on M1/M2 macrophage polarization in the presence of a
stimulator. To better understand the modulatory effects of LUM on
macrophage polarization, gene expression proﬁles were studied
with LPS-induced M1-like or IL-4 mediated M2-like macrophages
in the presence or absence of LUM. Gene expression analysis of pro-
inﬂammatory markers TNF-a and CD197 upon LUM co-stimulation
with LPS showed enhanced M1-like macrophage activation
whereas anti-inﬂammatory markers CD206 and CCL22 were
downregulated upon LUM co-stimulation with IL-4, indicating a
suppressed M2-like macrophage phenotype activation. These re-
sults were consistent with the protein secretion levels of IL-10 and
TNF-a, albeit IL-10 secretion failed to reach statistical signiﬁcance.
Notably, LUM alone had no effect on TNF-a, CD206, and CCL22
expression, with only a small effect on CD197 expression, which is
in line with previous reports51.
Our study does have limitations. Althoughwewere able to show
differences in LUM concentration among arthritic groups, the
selected patients in this study were not stratiﬁed with respect to
disease activity or severity. Nevertheless, all selected arthritic pa-
tients were at end-stage joint arthroplasty phase.
In conclusion, this study demonstrates that LUM is upregulated
in the SF of OA and RA patients, and that supraphysiological levels
of LUM exacerbate the LPS-induced chondrocyte inﬂammatory
response, mediated by TLR4, which leads to upregulated secretion
of catabolic molecules, cell death and apoptosis, but also to the
degradation of cartilage essential anabolic factors, such as collagen
type II and GAGs (Fig. 8). LUM co-stimulation also interfered with
macrophage polarization, leading to a reduced polarization into the
anti-inﬂammatory phenotype, while increasing the polarizationinto the pro-inﬂammatory phenotype and ensuing production of
inﬂammatory molecules. Importantly, LUM alone did not induce
any inﬂammatory response, further supporting the fact that LUM
acts as an immunologic adjuvant in OA (Fig. 8). These results
highlight the potential of LUM as an OA biomarker, but also as a
therapeutic target, particularly via suppressing LUM/LPS exacer-
bation of TLR4-mediated immune responses in the OA joint.
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